• Registrational Phase 3 Clinical Trial Update - Indonesia's Food and Drug Authority Meeting and Clinical Trial Sites Onboarded
• Phase 2 Clinical Trial receives additional approval allowing patients with Diabetic Foot Infections further access to RECCE® 327 Topical Gel
• United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Cooperative Research & Development Agreement

Recce Pharmaceuticals Ltd (ASX:RCE) released its Q4 FY2025 results and operational highlights. Key updates include: Registrational Phase 3 Clinical Trial Update - The company held successful meetings with Indonesia's Food and Drug Authority and expanded Phase 3 clinical trial sites across Indonesia. Phase 2 Clinical Trial Receives Additional Approval - The company received approval to allow Diabetic Foot Ulcer Infection patients further access to RECCE® 327 Topical Gel under the same Phase 2 Clinical Trial protocol. United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Cooperative Research & Development Agreement - The company entered into a CRADA with USAMRIID to test RECCE® 327 against biodefence pathogens. The company also announced a A$15.8 million capital raising from existing shareholders, a non-dilutive debt facility of up to ~A$30 million with Avenue Capital Group, and the receipt of a Chinese patent and Canadian R&D rebate.

The company ended the quarter with a cash balance of A$10.53 million. The A$15.8 million capital raise, ~A$11.49 million non-dilutive funding, and the expected FY25 R&D rebate of ~A$8.5 million provide an effective ~A$39.63 million cash runway.

With a successful capital raise, non-dilutive funding, and expected R&D rebate, the company is well-positioned to support its Phase 3 clinical trial activities in Indonesia and Australia for the treatment of Diabetic Foot Infections and Acute Bacterial Skin and Skin Structure Infections, as well as broader commercialisation efforts across the ASEAN region.